Mycophenolate Mofetil for the Treatment of Takayasu Arteritis: Report of Three Cases

Erica Daina; Arrigo Schieppati; Giuseppe Remuzzi

doi:10.7326/0003-4819-130-5-199903020-00013

Back

Mycophenolate Mofetil for the Treatment of Takayasu Arteritis: Report of Three Cases

Article 1999 en

Abstract

1 min read

Mycophenolate mofetil may be an alternative to steroids and cytotoxic agents in patients with Takayasu arteritis. Before results of controlled trials become available, mycophenolate mofetil should be considered only for patients who do not improve or stabilize with conventional therapy.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2007

Mycophenolate Mofetil versus Azathioprine for Prevention of Chronic Allograft Dysfunction in Renal Transplantation

Giuseppe Remuzzi, Paolo Cravedi, Marco Costantini, Mariadomenica Lesti, María Ganeva, Giulia Gherardi, Bogdan Ene‐Iordache, Eliana Gotti, Donato Donati, Maurizio Salvadori, Silvio Sandrini, Giuseppe Segoloni, Stefano Federico, Paolo Rigotti, Vito Sparacino, Piero Ruggenenti

Letter2006

The Novel Immunosuppressive Agent Mycophenolate Mofetil Markedly Potentiates the Antiherpesvirus Activities of Acyclovir, Ganciclovir, and Penciclovir In Vitro and In Vivo

Johan Neyts, Graciela Andreï, De Clercq Erik

Mycophenolate Mofetil for the Treatment of Takayasu Arteritis: Report of Three Cases

Abstract

Discussion(0)

Related publications

Mycophenolate Mofetil versus Azathioprine for Prevention of Chronic Allograft Dysfunction in Renal Transplantation

Is Mycophenolate Mofetil Better Than Azathioprine in Organ Transplantation?

C3G and Ig-MPGN—treatment standard

Role of Immune Checkpoint Blockade in the Treatment for Human Hepatocellular Carcinoma

The Novel Immunosuppressive Agent Mycophenolate Mofetil Markedly Potentiates the Antiherpesvirus Activities of Acyclovir, Ganciclovir, and Penciclovir In Vitro and In Vivo